Phase II trial of Erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2014
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 31 May 2011 New trial record